The top 100 bio­phar­ma VCs, Bob Brad­way places $2B bet in can­cer, gene edit­ing pi­o­neer's new big idea, and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Be­fore div­ing in, we had some news to share: End­points is launch­ing a pre­mi­um week­ly re­port fo­cus­ing on all things reg­u­la­to­ry. Cov­er­age will be led by our new se­nior ed­i­tor, Zachary Bren­nan, who joins us from POLITI­CO. Ar­salan Arif has more de­tails in his Pub­lish­er’s Note.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER